Pembrolizumab biosimilar (Shanghai Hongcheng Pharma)

帕博利珠单抗生物类似药 (上海宏成药业)

Report date: 2025/11/20 13:39:58

Base Information

Drug NamePembrolizumab biosimilar (Shanghai Hongcheng Pharma)
Drug Alias NameN/A
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsMicrosatellite instability-high cancerUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell Lung +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHC Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesHC Biopharma Inc
Inactive CompaniesN/A
Active IndicationsMicrosatellite instability-high cancerUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell Lung +[12] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A